ArticleNeuromodulation : journal of the International Neuromodulation Society2023
Eleven-Year Outcomes of Deep Brain Stimulation in Early-Stage Parkinson Disease.
Article in Neuromodulation : journal of the International Neuromodulation Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00282152 (Safety and Tolerability of Neurostimulation in Early Stage Parkinson's Disease), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Tolerability of Neurostimulation in Early Stage Parkinson's Disease
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Neuropsychological outcomes comparing deep brain stimulation and best medical treatment for Parkinson's disease: a systematic review and meta-analysis.Frontiers in psychology · 2026Pooled it
- Long-term neuropsychological outcomes of deep brain stimulation in early-stage Parkinson's disease.Parkinsonism & related disorders · 2023Trial
- Connectivity Profile for Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson Disease.Annals of neurology · 2023Trial
- Disease modification in advanced Parkinson's disease: a review and roadmap for paving the way for next-generation interventions.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Advanced Therapeutics in Parkinson's Disease: What's New?Current neurology and neuroscience reports · 2026Review
- Differentiating effects of levodopa and subthalamic nucleus deep brain stimulation on motor features in Parkinson disease.Clinical parkinsonism & related disorders · 2026Article
- Microwave Imaging for Parkinson's Disease Detection: A Phantom-Based Feasibility Study Using Temperature-Controlled Dielectric Variations.Sensors (Basel, Switzerland) · 2025Article
- Advanced therapies in Parkinson's disease: an individualized approach to their indication.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Deep brain stimulation for Tourette's syndrome.The Cochrane database of systematic reviews · 2024Article
- High frequency electrical stimulation reduces α-synuclein levels and α-synuclein-mediated autophagy dysfunction.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveThe deep brain stimulation (DBS) in early-stage Parkinson's disease (PD) pilot clinical trial randomized 30 patients (Hoehn & Yahr II off; medication duration 0.5-4 years; without dyskinesia/motor fluctuations) to optimal drug therapy (ODT) (early ODT) or bilateral subthalamic nucleus (STN) DBS plus ODT (early DBS+ODT). This study aims to report the 11-year outcomes of patients who completed the DBS in early-stage PD pilot clinical trial. MATERIALS AND
methodsAttempts were made to contact all 29 subjects who completed the two-year trial to participate in an 11-year follow-up study. Mixed-effects models compared overall trend in outcomes for randomization groups (fixed-effects: assigned treatment, year, their interaction; random-effect: subject) to account for repeated measures.
resultsTwelve subjects participated in this 11-year follow-up study (n = 8 early ODT, n = 4 early DBS+ODT). Participating subjects were 70.0 ± 4.8 years old with a PD medication duration of 13.7 ± 1.7 years (early DBS duration 11.5 ± 1.3 years, n = 4). Three early ODT subjects received STN-DBS as standard of care (DBS duration 6.5 ± 2.0 years). Early ODT subjects had worse motor complications (Unified Parkinson's Disease Rating Scale [UPDRS]-IV) than early DBS+ODT subjects over the 11-year follow-up period (between-group difference = 3.5 points; p
conclusionsEleven years after randomization, early DBS+ODT subjects had fewer motor complications than early ODT subjects. These results should be interpreted with caution because only 40% of pilot trial subjects participated in this 11-year follow-up study. The Food and Drug Administration has approved the conduct of a pivotal clinical trial evaluating DBS in early-stage PD (IDEG050016). CLINICAL
trial registrationThe Clinicaltrials.gov registration number for the study is NCT00282152.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.